{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:36:26Z","timestamp":1762032986800,"version":"3.38.0"},"reference-count":59,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Neuro-Psiquiatr."],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:p>Interferon beta (IFN\u03b2) and glatiramer acetate (GA) were the first immunomodulators approved to the treatment of relapsing-remitting multiple sclerosis (MS) and clinically isolated syndromes. Despite the enlargement of the therapeutic armamentarium, IFN\u03b2 and GA remain the most widely drugs and the therapeutic mainstay of MS. OBJECTIVE: To review the mechanisms of action of IFN\u03b2 and GA and main clinical results in MS. RESULTS: IFN\u03b2 modulates T and B-cell activity and has effects on the blood-brain barrier. The well proved mechanism of GA is an immune deviation by inducing expression of anti-inflammatory cytokines. Some authors favor the neuroprotective role of both molecules. Clinical trials showed a 30% reduction on the annualized relapse rate and of T2 lesions on magnetic resonance. CONCLUSION: Although the precise mechanisms how IFN\u03b2 and GA achieve their therapeutics effects remain unclear, these drugs have recognized beneficial effects and possess good safety and tolerability profiles. The large clinical experience in treating MS patients with these drugs along almost two decades deserves to be emphasized, at a time where the appearance of drugs with more selective mechanisms of action, but potentially less safer, pave the way to a better selection of the most appropriate individualized treatment.<\/jats:p>","DOI":"10.1590\/s0004-282x2011000400024","type":"journal-article","created":{"date-parts":[[2011,7,7]],"date-time":"2011-07-07T16:35:10Z","timestamp":1310056510000},"page":"536-543","source":"Crossref","is-referenced-by-count":31,"title":["Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works"],"prefix":"10.1590","volume":"69","author":[{"given":"Am\u00e9lia","family":"Mendes","sequence":"first","affiliation":[{"name":"Hospital de S\u00e3o Jo\u00e3o, Portugal"}]},{"given":"Maria Jos\u00e9","family":"S\u00e1","sequence":"additional","affiliation":[{"name":"Hospital de S\u00e3o Jo\u00e3o, Portugal; University Fernando Pessoa, Portugal"}]}],"member":"530","reference":[{"key":"ref1","series-title":"Neurology in clinical practice","first-page":"1588","volume-title":"Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system","author":"Lublin FD","year":"2008","edition":"5"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1474-4422(10)70094-6","article-title":"Multiple sclerosis: risk factors, prodromes, and potential causal pathways","volume":"9","author":"Ramagopalan SV","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref3","first-page":"96","article-title":"Treatment of multiple sclerosis with human beta interferon","volume":"12","author":"Goodin DS","year":"2005","journal-title":"Int MS J"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/01.wnl.0000277703.74115.d2","article-title":"Interferon-beta: mechanism of action and dosing issues","volume":"68","author":"Markowitz CE","year":"2007","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1177\/1352458519950101012","article-title":"Biologic effects of interferons: relevance to multiple sclerosis","volume":"1","author":"Rudick RA","year":"1995","journal-title":"Mult Scler","ISSN":"https:\/\/id.crossref.org\/issn\/1352-4585","issn-type":"print"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.0b013e3181c97d99","article-title":"Interferon beta mechanisms of action in multiple sclerosis","volume":"74","author":"Dhib-Jalbut S","year":"2010","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0165-5728(95)00072-A","article-title":"Interferon beta-1b reduces interferon gamma-induced antigen presenting capacity of human glial and B cells","volume":"61","author":"Jiang H","year":"1995","journal-title":"J Neuroimmunol","ISSN":"https:\/\/id.crossref.org\/issn\/0165-5728","issn-type":"print"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1212\/WNL.51.3.682","article-title":"Interferon beta in the treatment of multiple sclerosis-mechanisms of action","volume":"51","author":"Yong VW","year":"1998","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"12097","DOI":"10.1073\/pnas.0900562106","article-title":"Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses","volume":"106","author":"Joshi S","year":"2009","journal-title":"Proc Natl Acad Sci USA","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2332\/allergolint.R-07-159","article-title":"Th17 Cells and autoimmune encephalomyelitis (EAE\/MS)","volume":"57","author":"Aranami T","year":"2008","journal-title":"Allergol Int"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.4049\/jimmunol.0802226","article-title":"IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation","volume":"182","author":"Zhang X","year":"2009","journal-title":"J Immunol","ISSN":"https:\/\/id.crossref.org\/issn\/0022-1767","issn-type":"print"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0165-5728(01)00422-2","article-title":"Interferon-beta therapy downregulates the anti-apoptosis protein FLIP in T cells from patients with multiple sclerosis","volume":"120","author":"Sharief MK","year":"2001","journal-title":"J Neuroimmunol","ISSN":"https:\/\/id.crossref.org\/issn\/0165-5728","issn-type":"print"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S0165-5728(00)00261-7","article-title":"RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b","volume":"107","author":"Iarlori C","year":"2000","journal-title":"J Neuroimmunol","ISSN":"https:\/\/id.crossref.org\/issn\/0165-5728","issn-type":"print"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1001\/archneurol.2009.138","article-title":"Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis","volume":"66","author":"Cepok S","year":"2009","journal-title":"Arch Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9942","issn-type":"print"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1093\/brain\/awn077","article-title":"Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity","volume":"131","author":"Krumbholz M","year":"2008","journal-title":"Brain","ISSN":"https:\/\/id.crossref.org\/issn\/0006-8950","issn-type":"print"},{"key":"ref16","first-page":"236","article-title":"Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN\u00df. J","volume":"108","author":"Ozenci V","year":"2000","journal-title":"Neuroimmunol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00415-004-0285-7","article-title":"Effects of IFN\u00df-1a on serum matrix MMP-9 and tissue inhibitor of matrix metalloproteinase in relapsing-remitting multiple sclerosis patients: one year follow-up results","volume":"251","author":"Karabudak R","year":"2004","journal-title":"J Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0340-5354","issn-type":"print"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jneuroim.2004.11.017","article-title":"IFN\u00df-1a induces increases in vascular cell adhesion molecule: implications for its modes of action in multiple sclerosis","volume":"161","author":"Graber J","year":"2005","journal-title":"J Neuroimmunol","ISSN":"https:\/\/id.crossref.org\/issn\/0165-5728","issn-type":"print"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/1531-8249(199909)46:3<319::AID-ANA7>3.0.CO;2-N","article-title":"Migratory behavior of lymphocytes isolated from multiple sclerosis patients: effects of interferon b-1b therapy","volume":"46","author":"Uhm JH","year":"1999","journal-title":"Ann Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0165-5728(95)00054-6","article-title":"Interferon beta downregulates interferon gamma-induced class II MHC molecule expression and morphological changes in primary cultures of human brain microvessel endothelial cells","volume":"60","author":"Huynh HK","year":"1995","journal-title":"J Neuroimmunol","ISSN":"https:\/\/id.crossref.org\/issn\/0165-5728","issn-type":"print"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/ana.410410517","article-title":"Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b","volume":"41","author":"Calabresi PA","year":"1997","journal-title":"Ann Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13550280701801107","article-title":"Inhibition of multiple-sclerosis-associated retrovirus as biomarker of interferon therapy","volume":"14","author":"Mameli G","year":"2008","journal-title":"J Neurovirol","ISSN":"https:\/\/id.crossref.org\/issn\/1355-0284","issn-type":"print"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/13550280701649670","article-title":"Interferon beta treatment: bioavailability and antiviral activity in multiple sclerosis patients","volume":"13","author":"Garcia-Montojo M","year":"2007","journal-title":"J Neurovirol","ISSN":"https:\/\/id.crossref.org\/issn\/1355-0284","issn-type":"print"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s004150170052","article-title":"Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b","volume":"248","author":"Narayanan S","year":"2001","journal-title":"J Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0340-5354","issn-type":"print"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1212\/WNL.43.4.655","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo controlled trial","volume":"43","year":"1993","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1212\/WNL.43.4.662","article-title":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo controlled trial","volume":"43","author":"Paty DW","year":"1993","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/ana.410390304","article-title":"The Multiple Sclerosis Collaborative Research Group: intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis","volume":"39","author":"Jacobs LD","year":"1996","journal-title":"Ann Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1212\/WNL.56.12.1628","article-title":"PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS","volume":"56","year":"2001","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1191\/1352458505ms1126oa","article-title":"Once weekly interferon beta-1alpha for Multiple Sclerosis Study Group; University of British Columbia MS\/MRI Research Group: Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study","volume":"11","author":"Freedman MS","year":"2005","journal-title":"Mult Scler","ISSN":"https:\/\/id.crossref.org\/issn\/1352-4585","issn-type":"print"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(98)10039-9","article-title":"European Study Group on interferon beta-1b in secondary progressive MS: Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group","volume":"343","author":"Jacobs LD","year":"2000","journal-title":"N Engl J Med","ISSN":"https:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","article-title":"Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study","volume":"370","author":"Kappos L","year":"2007","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1089\/107999099312920","article-title":"Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers","volume":"19","author":"St\u00fcrzebecher S","year":"1999","journal-title":"J Interferon Cytokine Res","ISSN":"https:\/\/id.crossref.org\/issn\/1079-9907","issn-type":"print"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1212\/WNL.58.2.169","article-title":"Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technological Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines","volume":"58","author":"Goodin DS","year":"2002","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(02)08430-1","article-title":"Independent Comparison of Interferon (INCOMIN) Trial Study Group: Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)","volume":"359","author":"Durelli L","year":"2002","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref36","first-page":"1496","article-title":"Evidence of Interferon Dose-response: European North American Comparattive Efficacy; University of British Columbia MS\/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial","volume":"59","author":"Panitch H","year":"2002","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0404.2005.00565.x","article-title":"Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study","volume":"113","author":"Patti F","year":"2006","journal-title":"Acta Neurol Scand","ISSN":"https:\/\/id.crossref.org\/issn\/0001-6314","issn-type":"print"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1468-1331.2005.01386.x","article-title":"EFNS Task Force on Anti-IFN-beta Antibodies in Multiple Sclerosis: Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis","volume":"12","author":"S\u00f8rensen PS","year":"2005","journal-title":"Eur J Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/1351-5101","issn-type":"print"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1212\/01.wnl.0000258545.73854.cf","article-title":"Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"68","author":"Goodin DS","year":"2007","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S1474-4422(09)70226-1","article-title":"250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study","volume":"8","author":"O'Connor P","year":"2009","journal-title":"Lancet Neurol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/01.wnl.0000180575.77021.c4","article-title":"The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort","volume":"65","author":"Boskovic R","year":"2005","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/WNL.0b013e3181c97e39","article-title":"The mechanism of action of glatiramer acetate treatment in multiple sclerosis","volume":"74","author":"Racke MK","year":"2010","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.autrev.2007.02.003","article-title":"Glatiramer acetate: mechanisms of action in multiple sclerosis","volume":"6","author":"Schrempf W","year":"2007","journal-title":"Autoimmun Rev"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/WNL.56.6.702","article-title":"Mechanisms of action of glatiramer acetate in multiple sclerosis","volume":"56","author":"Neuhaus O","year":"2001","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1521-6616(03)00020-2","article-title":"In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis","volume":"106","author":"Schmied M","year":"2003","journal-title":"Clin Immunol"},{"key":"ref46","first-page":"244","article-title":"Glatiramer acetate","volume":"17","author":"Comi G","year":"2002","journal-title":"Neurologia","ISSN":"https:\/\/id.crossref.org\/issn\/0213-4853","issn-type":"print"},{"key":"ref47","first-page":"303","article-title":"Glatiramer acetate blocks the activation of THP-1 cells by interferon-: . Eur","volume":"342","author":"Li Q","year":"1998","journal-title":"J Pharmacol","ISSN":"https:\/\/id.crossref.org\/issn\/0021-793X","issn-type":"print"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1073\/pnas.0812183106","article-title":"Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis","volume":"106","author":"Burger D","year":"2009","journal-title":"Proc Natl Acad Sci U S A","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"key":"ref49","first-page":"283","article-title":"Glatiramer in the treatment of multiple sclerosis Internat","volume":"1","author":"Rizvi SA","year":"2006","journal-title":"J Nanomed"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1552-6569.2007.00206.x","article-title":"Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-Term H-MRS monitoring in multiple sclerosis","volume":"18","author":"Khan O","year":"2008","journal-title":"J Neuroimaging","ISSN":"https:\/\/id.crossref.org\/issn\/1051-2284","issn-type":"print"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","article-title":"Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled. The Copolymer I Multiple Sclerosis Study Group","volume":"45","author":"Johnson KP","year":"1995","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1191\/135248506ms1318oa","article-title":"The Copaxone Study Group: a prospective open-label study of glatiramer acetate:over a decade of continuous use in multiple sclerosis patients","volume":"12","author":"Ford CC","year":"2006","journal-title":"Mult Scler","ISSN":"https:\/\/id.crossref.org\/issn\/1352-4585","issn-type":"print"},{"key":"ref53","first-page":"290","article-title":"2001: European\/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of GA on MRI-measured activity and burden in patients with relapsing multiple sclerosis","volume":"49","author":"Comi G","year":"2001","journal-title":"Ann Neurol","ISSN":"https:\/\/id.crossref.org\/issn\/0364-5134","issn-type":"print"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi G","year":"2009","journal-title":"Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"key":"ref55","first-page":"A97","article-title":"Effect of GA on primary progressive MS: initial analysis of the completed PROMISE trial","volume":"62","author":"Wolinsky JS","year":"2004","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1352458509106543","article-title":"Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study","volume":"15","author":"Weber-Schoendorfer C","year":"2009","journal-title":"Mult Scler","ISSN":"https:\/\/id.crossref.org\/issn\/1352-4585","issn-type":"print"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(08)70200-X","article-title":"Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study: a multicentre, randomised, parallel, open-label trial","volume":"7","author":"Mikol DD","year":"2008","journal-title":"Lancet Neurol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/01.wnl.0000345970.73354.17","article-title":"Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study","volume":"72","author":"Cadavid D","year":"2009","journal-title":"Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/0028-3878","issn-type":"print"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/PPA.S8230","article-title":"Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence","volume":"4","author":"Patti F","year":"2010","journal-title":"Patient Prefer Adherence"}],"container-title":["Arquivos de Neuro-Psiquiatria"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/anp\/v69n3\/a24v69n3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:22:10Z","timestamp":1741306930000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-282X2011000400024&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0004-282X2011000400024"],"URL":"https:\/\/doi.org\/10.1590\/s0004-282x2011000400024","relation":{},"ISSN":["0004-282X"],"issn-type":[{"type":"electronic","value":"0004-282X"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}